1 to 3 of 3 literature results

• Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

  Imatinib mesylate (Gleevec) is a small-molecule inhibitor of the fusion protein Bcr-Abl, the causal agent in chronic myelogenous leukemia. Here we rep…

  Authors: Risto Kerkelä, Luanda Grazette, Rinat Yacobi, Cezar Iliescu, Richard Patten, Cara Beahm, Brian Walters, Sergei Shevtsov, Stéphanie Pesant, Fred J Clubb,…

  Source: Nature medicine. 2006 Aug

  View Full Text

• Autoinhibition of Bcr-Abl through its SH3 domain.

  Bcr-Abl is a dysregulated tyrosine kinase whose mechanism of activation is unclear. Here, we demonstrate that, like c-Abl, Bcr-Abl is negatively regul…

  Authors: Kristen M Smith, Rinat Yacobi, Richard A Van Etten

  Source: Molecular cell. 2003 Jul

  View Full Text

• Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.

  Imatinib mesylate (IM), a potent inhibitor of the BCR/ABL tyrosine kinase, has become standard first-line therapy for patients with chronic myeloid le…

  Authors: Cristian Bellodi, Maria Rosa Lidonnici, Ashley Hamilton, G Vignir Helgason, Angela Rachele Soliera, Mattia Ronchetti, Sara Galavotti, Kenneth W Young, Tommaso Selmi, Rinat Yacobi,…

  Source: The Journal of clinical investigation. 2009 May

  View Free Full Text